MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

109.18 -1.77 (-1.60%)
Official Closing Price Updated: 7:00 PM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Top S&P500 movers in Thursday's after hours session ↗
Via Chartmill
News headline image
Merck (MRK) Q1 2026 Earnings Call Transcript ↗
Merck (MRK) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Merck (NYSE:MRK) Q1 2026 Results Show Underlying Strength Despite Acquisition-Driven Loss ↗
Via Chartmill
News headline image
Merck (NYSE:MRK) Surprises With Q1 CY2026 Sales
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16.... 
Via StockStory
Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗
Via Chartmill
News headline image
Merck (MRK) Q1 Earnings Report Preview: What To Look For
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property
News headline image
Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
Via StockStory
Topics Government Intellectual Property
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
3 Reasons We Love Merck (MRK)
Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Better Pharma Dividend Stock: Novartis vs. Merck ↗
Both are great stocks to buy in the current environment, but which one is the better bet? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear
As the first-quarter earnings season of 2026 kicks off, Wall Street is bracing for a high-stakes performance that could determine the trajectory of the market for the remainder of the year. With the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
1 Momentum Stock on Our Buy List and 2 We Question
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
News headline image
Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall... 
Via Finterra
Topics Economy World Trade
News headline image
Why Terns Pharmaceuticals Stock Rocked the Market in March ↗
A large peer is snapping up the company in a premium-priced deal. 
Via The Motley Fool
Topics Intellectual Property
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Could this player be heading into a new era of growth? 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
Via MarketBeat
News headline image
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Eli Lilly is much more than just a weight loss stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
They could make important breakthroughs in their target markets. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story